Novo Nordisk A/S (NYSE:NVO) Position Lowered by GM Advisory Group LLC

GM Advisory Group LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 11.0% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,522 shares of the company’s stock after selling 311 shares during the period. GM Advisory Group LLC’s holdings in Novo Nordisk A/S were worth $217,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Folketrygdfondet increased its holdings in shares of Novo Nordisk A/S by 0.5% in the 4th quarter. Folketrygdfondet now owns 8,903,938 shares of the company’s stock valued at $765,917,000 after acquiring an additional 40,313 shares during the last quarter. Sustainable Growth Advisers LP increased its stake in Novo Nordisk A/S by 23.6% during the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock valued at $459,416,000 after purchasing an additional 1,021,498 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $404,910,000. WCM Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 1.0% in the 4th quarter. WCM Investment Management LLC now owns 4,031,124 shares of the company’s stock worth $345,588,000 after buying an additional 40,475 shares during the last quarter. Finally, Amundi boosted its holdings in shares of Novo Nordisk A/S by 26.4% in the 4th quarter. Amundi now owns 3,311,456 shares of the company’s stock valued at $283,615,000 after buying an additional 692,567 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

NVO has been the topic of several research reports. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Trading Down 2.6 %

NYSE:NVO opened at $78.91 on Thursday. Novo Nordisk A/S has a 1 year low of $73.80 and a 1 year high of $148.15. The business has a fifty day moving average of $83.67 and a 200-day moving average of $101.82. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The stock has a market cap of $354.12 billion, a price-to-earnings ratio of 23.99, a PEG ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a $0.7874 dividend. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.